Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.44 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.44 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1781771 | 0.98 | PKM (0.45) | PKMRAB9AALDH1A1LMNAKMT2A | |
| SCHEMBL31262950 | 0.82 | CA1 (0.44) | ALDH1A1KMT2AMEN1MAPTHPGD | |
| SCHEMBL807665 | 0.82 | MAPT (0.48) | RAB9AALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL10348248 | 0.81 | SMN1; SMN2 (0.45) | PKMRAB9AALDH1A1LMNAKMT2A | |
| SCHEMBL11258990 | 0.81 | CA12 (0.62) | PKMRAB9AALDH1A1LMNAKMT2A | |
| SCHEMBL31262962 | 0.81 | TSHR (0.55) | PKMRAB9AALDH1A1LMNAKMT2A | |
| SCHEMBL31263081 | 0.81 | MAPT (0.44) | ALDH1A1LMNAKMT2AMEN1MAPT | |
| SCHEMBL20762355 | 0.81 | CA12 (0.43) | RAB9AALDH1A1NPC1SMN1; SMN2HPGD | |
| SCHEMBL4493412 | 0.81 | CA12 (0.46) | PKMRAB9ALMNAKMT2AMEN1 | |
| SCHEMBL28904888 | 0.81 | ALDH1A1 (0.47) | RAB9AALDH1A1MAPTNPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4702000-A1 | ALKYLATION PROCESS | University of Liverpool (GB) | 2026-03-04 | — | — | EP | disclosed |
| US-12447207-B2 | Human cytomegalovirus gB polypeptide | PFIZER INC. (US) | 2025-10-21 | — | — | US | disclosed |
| WO-2025203556-A1 | PROGRAM, DEBUGGING DEVICE, DEBUGGING SYSTEM, AND DEBUGGING METHOD | 三菱電機株式会社 | 2025-10-02 | — | — | WO | disclosed |
| US-20250066562-A1 | METHOD AND MATERIAL FOR DIFFERENTIATED SEQUESTRATION OF SUBSTANCES OF DIFFERENT SUBSTANCE GROUPS WITH THE AID OF HYDROGELS CONTAINING SULPHATED OR SULPHONATED COMPONENTS | LEIBNIZ-INSTITUT FÜR POLYMERFORSCHUNG E.V. (DE) | 2025-02-27 | — | — | US | disclosed |
| US-20250066561-A1 | METHOD AND MATERIAL FOR DIFFERENTIATED SEQUESTRATION OF SUBSTANCES OF DIFFERENT SUBSTANCE GROUPS WITH THE AID OF HYDROGELS CONTAINING SULPHATED OR SULPHONATED COMPONENTS | LEIBNIZ-INSTITUT FÜR POLYMERFORSCHUNG E.V. (DE) | 2025-02-27 | — | — | US | disclosed |
| WO-2025028235-A1 | IMAGING ELEMENT AND IMAGING DEVICE | ソニーセミコンダクタソリューションズ株式会社 | 2025-02-06 | — | — | WO | disclosed |
| WO-2024224034-A1 | ALKYLATION PROCESS | THE UNIVERSITY OF LIVERPOOL (GB) | 2024-10-31 | — | — | WO | disclosed |
| US-20240299587-A1 | NOVEL DRUGGABLE REGIONS IN THE HUMAN CYTOMEGALOVIRUS GLYCOPROTEIN B POLYPEPTIDE AND METHODS OF USE THEREOF | PFIZER (US) | 2024-09-12 | — | — | US | disclosed |
| US-20240228628-A9 | ANTIBODIES TARGETING FLT3 AND USE THEREOF | DRAGONFLY THERAPEUTICS INC (US) | 2024-07-11 | — | — | US | disclosed |
| CN-117964504-A | Preparation method of gem-difluoroallylglycine or polypeptide derivative | 南京林业大学 | 2024-05-03 | — | — | CN | disclosed |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
| US-20060205672-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2006-09-14 | — | — | US | disclosed |
| US-7012066-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2006-03-14 | — | — | US | disclosed |
| CN-1633446-A | Novel peptides as inhibitors of hepatitis C virus NS 3-serine protease | SCHERING CORP (US) | 2005-06-29 | — | — | CN | disclosed |
| US-20040254117-A9 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | DENDREON PHARMACEUTICALS LLC | 2004-12-16 | — | — | US | disclosed |
| EP-1481000-A2 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2004-12-01 | — | — | EP | disclosed |
| EP-1385870-A2 | PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | Schering Corporation (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20030216325-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SAKSENA ANIL K | 2003-11-20 | — | — | US | disclosed |
| WO-2003062265-A2 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2003-07-31 | — | — | WO | disclosed |
| WO-2002008244-A2 | PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205672-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | PKM 3364/4885RAB9A 2106/4885ALDH1A1 2369/4885 |
| US-20030216325-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | PKM 3364/4885RAB9A 2106/4885ALDH1A1 2369/4885 |
| US-12447207-B2 | Human cytomegalovirus gB polypeptide | GBA3, HBB, PDGFA | PKM 3851/4885RAB9A 1275/4885ALDH1A1 4825/4885 |
| US-20240299587-A1 | NOVEL DRUGGABLE REGIONS IN THE HUMAN CYTOMEGALOVIRUS GLYCOPROTEIN B POLYPEPTIDE AND METHODS OF USE THEREOF | HAVCR2, LGALS3BP, GBA3 | PKM 4113/4885RAB9A 1463/4885ALDH1A1 3914/4885 |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | PKM 3364/4885RAB9A 2106/4885ALDH1A1 2369/4885 |
| US-20040254117-A9 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | PKM 3364/4885RAB9A 2106/4885ALDH1A1 2369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.